CymaBay Therapeutics Management
Management criteria checks 3/4
CymaBay Therapeutics' CEO is Sujal Shah, appointed in Mar 2017, has a tenure of 6.75 years. total yearly compensation is $2.56M, comprised of 23% salary and 77% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $13.20M. The average tenure of the management team and the board of directors is 3.5 years and 7 years respectively.
Key information
Sujal Shah
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 23.0% |
| CEO tenure | 7yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.5yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%
Feb 15
Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher
Dec 22CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?
Dec 28CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01
Aug 11Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Jul 13CymaBay: Long-Term Potential Based On Prior PBC Trial Results
Jun 27Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?
Mar 17Why I've Taken A 'Starter' Position In CymaBay Therapeutics
Jan 20Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Dec 03We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth
May 15We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely
Jan 29
CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow
Nov 17CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion
Nov 08CymaBay Therapeutics EPS in-line
Nov 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$90m |
| Jun 30 2023 | n/a | n/a | -US$81m |
| Mar 31 2023 | n/a | n/a | -US$107m |
| Dec 31 2022 | US$3m | US$590k | -US$106m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$104m |
| Mar 31 2022 | n/a | n/a | -US$100m |
| Dec 31 2021 | US$2m | US$550k | -US$90m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$68m |
| Mar 31 2021 | n/a | n/a | -US$55m |
| Dec 31 2020 | US$3m | US$510k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$65m |
| Jun 30 2020 | n/a | n/a | -US$80m |
| Mar 31 2020 | n/a | n/a | -US$93m |
| Dec 31 2019 | US$3m | US$510k | -US$103m |
| Sep 30 2019 | n/a | n/a | -US$93m |
| Jun 30 2019 | n/a | n/a | -US$85m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$2m | US$452k | -US$73m |
| Sep 30 2018 | n/a | n/a | -US$58m |
| Jun 30 2018 | n/a | n/a | -US$48m |
| Mar 31 2018 | n/a | n/a | -US$39m |
| Dec 31 2017 | US$5m | US$393k | -US$28m |
Compensation vs Market: Sujal's total compensation ($USD2.56M) is below average for companies of similar size in the US market ($USD6.32M).
Compensation vs Earnings: Sujal's compensation has increased whilst the company is unprofitable.
CEO
Sujal Shah (50 yo)
7yrs
Tenure
US$2,561,783
Compensation
Mr. Sujal A. Shah serves as Director at Tvardi Therapeutics, Inc. since January 2021. He has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7yrs | US$2.56m | 0.35% $ 13.2m | |
| President of Research & Development and Chief Scientific Officer | 11.2yrs | US$1.23m | 0.041% $ 1.5m | |
| General Counsel | 3.4yrs | US$1.10m | 0.061% $ 2.3m | |
| CFO, Principal Accounting & Financial Officer | less than a year | no data | 0.018% $ 653.5k | |
| Senior Vice President of Human Resources | 3.7yrs | no data | no data | |
| Senior Vice President of Business Development | 7.2yrs | no data | no data | |
| Senior Vice President of Manufacturing & Nonclinical Development | 8.9yrs | no data | no data | |
| Chief Regulatory & Quality Assurance Officer | 3.4yrs | US$1.24m | 0.018% $ 681.8k | |
| Senior Vice President of Portfolio & Product Leadership | 3.3yrs | no data | no data | |
| Head of Commercial | less than a year | no data | no data |
3.5yrs
Average Tenure
60.5yo
Average Age
Experienced Management: CBAY's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$2.56m | 0.35% $ 13.2m | |
| Independent Director | 2.9yrs | US$207.94k | 0% $ 0 | |
| Member of Clinical Advisory Board and Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.3yrs | US$215.44k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Chairman | 9yrs | US$245.44k | 0.026% $ 974.1k |
7.0yrs
Average Tenure
69yo
Average Age
Experienced Board: CBAY's board of directors are considered experienced (7 years average tenure).